More accurate method required for tracking skin cancer cases: study

This is Henry Ford Hospital dermatologist and lead author Melody Eide, MD. Credit: Henry Ford Hospital

Henry Ford Hospital dermatology researchers are urging caution about using claims data for identifying nonmelanoma skin cancer, suggesting that the commonly used method, which previously had not been validated, may be unreliable.

Instead, researchers say, an electronic pathology report (EPR) is far superior for more accurately identifying cases.

Claims data is common health insurance billing information. EPR shows the biopsy of a skin specimen result.

In a study published online Thursday in the Journal of Investigative Dermatology, lead author and Henry Ford Melody Eide, M.D., says "claims data may incorrectly estimate actual disease burden, with up to half of cases found to be false."

Key findings:

  • EPR was 30 to 46 percent better at identifying a patient had an actual nonmelanoma skin cancer compared to claims data methods.
  • EPR missed identifying less than 1 percent of actual skin cancer cases, significantly better than claims data.
  • EPR was able to specify the nonmelanoma skin cancer types of basal cell and squamous cell .
"We suggest that formal surveillance efforts at the state and national level should be considered and re-addressed, and the use of an electronic pathology report may be a potential alternative for more effectively tracking these cases," Dr. Eide says.

Skin cancer is the most common of all cancers, and accounts for nearly half of all cancers in the United States, according to the . An estimated 2 million cases of basal cell and squamous cell carcinoma – the most common types of nonmelanoma skin cancer – are found in the United States every year. Both have high cure rates if caught and treated early.

However, the epidemiology of basal cell and squamous cell carcinoma is largely understudied because common cancer registries like the Surveillance Epidemiology and End Results (SEER) program do not record data for them, due in large part that these cancers are associated with low mortality and the difficulty of confirming the large number of cases.

As a result, doctors have relied on administrative databases for identifying cases of nonmelanoma , not knowing the method's reliability. Using data gleaned from its health system to evaluate its accuracy, Henry Ford researchers sought to compare cases identified by claims data with cases identified by EPR, which contained the of a skin specimen of basal cell carcinoma and between Jan. 1, 2007 and Dec. 31, 2008.

Related Stories

Researchers identify skin cancer genes

Nov 10, 2011

(Medical Xpress) -- The genes which contribute to the most frequently occurring life threatening form of skin cancer have been identified for the first time by a research collaboration between the University ...

Study shows link between vitamin D, skin cancer

Mar 04, 2010

A Henry Ford Hospital study has shown a link between Vitamin D levels and basal cell carcinoma, a finding that could lead researchers to better understand the development of the most common form of skin cancer.

Recommended for you

New breast cancer imaging method promising

49 minutes ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

1 hour ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

Breast cancer replicates brain development process

1 hour ago

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Is genetic instability the key to beating cancer?

3 hours ago

Cancerous tumors may be poised at the edge of their own destruction, an insight that could help researchers find new, more effective treatments, suggest SFI External Professor Ricard Solé and colleagues in an April 9 paper ...

Phase 3 study may be game-changer for acute myeloid leukemia

6 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments